Company registration number 06965839 (England and Wales)
PHARMACYREPUBLIC LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2025
PHARMACYREPUBLIC LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 5
PHARMACYREPUBLIC LIMITED
BALANCE SHEET
AS AT 31 JULY 2025
31 July 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
3
125,329
43,804
Current assets
Stocks
170,285
181,448
Debtors
4
709,784
794,743
Cash at bank and in hand
291,929
173,132
1,171,998
1,149,323
Creditors: amounts falling due within one year
5
(584,326)
(538,309)
Net current assets
587,672
611,014
Total assets less current liabilities
713,001
654,818
Provisions for liabilities
4,260
2,853
Net assets
717,261
657,671
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
717,161
657,571
Total equity
717,261
657,671

For the financial year ended 31 July 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 14 April 2026 and are signed on its behalf by:
Usama Tariq
Director
Company registration number 06965839 (England and Wales)
PHARMACYREPUBLIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2025
- 2 -
1
Accounting policies
Company information

Pharmacyrepublic Limited is a private company limited by shares incorporated in England and Wales. The registered office is 138 Barking Road, London, UK, E6 3BD.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and equipment
20% on reducing balance
Fixtures and fittings
20% on reducing balance
Motor vehicles
20% on reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

1.6
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

PHARMACYREPUBLIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2025
1
Accounting policies
(Continued)
- 3 -
Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

 

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

1.7
Retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

1.8
Hire purchase and leasing commitments

Rentals paid under operating leases were charged to profit or loss on a straight line basis over the period of the lease.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
43
42
PHARMACYREPUBLIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2025
- 4 -
3
Tangible fixed assets
Plant and equipment
Fixtures and fittings
Motor vehicles
Total
£
£
£
£
Cost
At 1 August 2024
98,688
21,358
36,399
156,445
Additions
3,307
100,828
11,500
115,635
Disposals
-
0
-
0
(7,500)
(7,500)
At 31 July 2025
101,995
122,186
40,399
264,580
Depreciation and impairment
At 1 August 2024
80,083
4,272
28,286
112,641
Depreciation charged in the year
4,383
23,583
3,367
31,333
Eliminated in respect of disposals
-
0
-
0
(4,723)
(4,723)
At 31 July 2025
84,466
27,855
26,930
139,251
Carrying amount
At 31 July 2025
17,529
94,331
13,469
125,329
At 31 July 2024
18,605
17,086
8,113
43,804
4
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
436,843
550,144
Other debtors
272,941
244,599
709,784
794,743
5
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
483,068
429,342
Corporation tax
55,359
67,017
Other creditors
45,899
41,950
584,326
538,309
PHARMACYREPUBLIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2025
5
Creditors: amounts falling due within one year
(Continued)
- 5 -
6
Directors' transactions

The following advances and credits to directors subsisted during the years ended 31 July 2024 and 31 July 2025:

Advances
% Rate
Opening balance
Closing balance
£
£
Shazlee Ahsan -
-
14,994
14,994
Asif bashir -
-
14,621
14,621
Usama Tariq -
-
14,621
14,621
44,236
44,236

The loans are unsecured. Interest is charged at 2.25% and 3.75% and repayable on demand.

7
Ultimate Controlling Party

The company is jointly controlled by Asif Bashir, Shazlee Ahsan and Usama Tariq.

2025-07-312024-08-01falsefalsefalse14 April 2026CCH SoftwareCCH Accounts Production 2026.100No description of principal activityShazlee AhsanAsif bashirUsama Tariq069658392024-08-012025-07-31069658392025-07-31069658392024-07-3106965839core:PlantMachinery2025-07-3106965839core:FurnitureFittings2025-07-3106965839core:MotorVehicles2025-07-3106965839core:PlantMachinery2024-07-3106965839core:FurnitureFittings2024-07-3106965839core:MotorVehicles2024-07-3106965839core:CurrentFinancialInstrumentscore:WithinOneYear2025-07-3106965839core:CurrentFinancialInstrumentscore:WithinOneYear2024-07-3106965839core:CurrentFinancialInstruments2025-07-3106965839core:CurrentFinancialInstruments2024-07-3106965839core:ShareCapital2025-07-3106965839core:ShareCapital2024-07-3106965839core:RetainedEarningsAccumulatedLosses2025-07-3106965839core:RetainedEarningsAccumulatedLosses2024-07-3106965839bus:Director32024-08-012025-07-3106965839core:PlantMachinery2024-08-012025-07-3106965839core:FurnitureFittings2024-08-012025-07-3106965839core:MotorVehicles2024-08-012025-07-31069658392023-08-012024-07-3106965839core:PlantMachinery2024-07-3106965839core:FurnitureFittings2024-07-3106965839core:MotorVehicles2024-07-31069658392024-07-3106965839bus:PrivateLimitedCompanyLtd2024-08-012025-07-3106965839bus:SmallCompaniesRegimeForAccounts2024-08-012025-07-3106965839bus:FRS1022024-08-012025-07-3106965839bus:AuditExemptWithAccountantsReport2024-08-012025-07-3106965839bus:Director12024-08-012025-07-3106965839bus:Director22024-08-012025-07-3106965839bus:FullAccounts2024-08-012025-07-31xbrli:purexbrli:sharesiso4217:GBP